Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
GRUNENTHAL GMBH et al v. ACTAVIS ELIZABETH LLC et al
Case Number:
2:13-cv-04507
Court:
Nature of Suit:
Judge:
Firms
- Duane Morris
- Epstein Becker
- McCarter & English
- Midlige Richter
- Robinson Miller
- Sills Cummis
- Troutman Pepper
Companies
- Alkem Laboratories Ltd.
- Allergan PLC
- Ascend Laboratories LLC
- Assertio Holdings Inc.
- Grunenthal Group
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
-
January 23, 2020
Assertio Blasts Rival's Bid To Shorten Nucynta Injunction
Alkem Laboratories shouldn't be allowed to sell a generic version of Assertio Therapeutics' opioid painkiller Nucynta ER three years earlier than an injunction allows after changing its drug's label to dodge a patent, Assertio has told a New Jersey federal court.
-
April 12, 2017
Generic Nucynta Officially Barred After Depomed Patent Win
A New Jersey federal judge on Tuesday entered a final judgment and injunction barring Actavis Inc., Roxane Laboratories Inc. and Alkem Laboratories Ltd. from releasing generic versions of Depomed Inc.'s opioid painkiller Nucynta until related patents expire.
-
September 30, 2016
Depomed Gets Patent Win Over Generic Nucynta Drugmakers
Depomed Inc. won a major ruling Friday when a New Jersey federal judge said patents relating to its painkiller drug Nucynta are valid and that several generic drugmakers have infringed claims on the patents, giving the pharmaceutical giant a market lock on Nucynta products through 2025.
-
May 19, 2016
Actavis, Others Can't Yet Market Generic Nucynta, Judge Says
Actavis and two other drugmakers can't launch a generic version of Depomed Inc.'s painkiller Nucynta until the New Jersey federal judge who oversaw a patent infringement trial between the companies makes a final ruling, an order meant to maintain the status quo after the statutory 30-month stay on generic approval ends Friday.
-
July 26, 2013
Grunenthal Says Actavis, Alkem Infringed Painkiller IP
German pharmaceuticals giant Grunenthal GmbH accused rivals Actavis Inc. and Alkem Laboratories Ltd. of infringing patents for its painkiller Nucynta by seeking federal approval for generic copies of the drug, according to a suit filed in New Jersey federal court Thursday.